Gilead Sciences | Srodki Pieniężne I Ekwiwalent



Cash And Equivalent Zmiana Data
AbbVie USD 5.18B 349M 2025-03
Agios Pharmaceuticals USD 80.87M 1.91M 2025-06
ALKERMES USD 521.2M 121.39M 2025-06
Alnylam Pharmaceuticals USD 1.11B 94.03M 2025-06
Amgen USD 8.03B 782M 2025-06
Biogen USD 2.76B 160.5M 2025-06
BioMarin Pharmaceutical USD 1.21B 601.78M 2025-06
Bristol-Myers Squibb USD 12.6B 1.72B 2025-06
Eli Lilly USD 3.38B 282.6M 2025-06
Gilead Sciences USD 5.14B 2.78B 2025-06
GlaxoSmithKline GBP 3.6B 865M 2025-06
Glaxosmithkline GBP 3.87B 678M 2024-12
Incyte USD 2.42B 13.08M 2025-06
J&J USD 38.47B 32.35B 2025-03
Merck USD 8.01B 622M 2025-06
Moderna USD 1.28B 344M 2025-06
Neurocrine Biosciences USD 264M 69.9M 2025-06
Novartis USD 6.66B 410M 2025-06
Pfizer USD 1.64B 208M 2025-06
PTC Therapeutics USD 1.02B 1.01B 2025-06
Regeneron Pharmaceuticals USD 2B 1.09B 2025-06
Sanofi 15.36B 7.37B 2025-06
Sarepta Therapeutics USD 510.6M 269.73M 2025-06
United Therapeutics USD 1.59B 306.8M 2025-06
Vertex Pharmaceuticals USD 6.38B 1.71B 2025-06


Gilead Sciences Srodki Pieniężne I Ekwiwalent - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Aug 2025.